 Michael Cripps
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholecystectomy, Laparoscopic | 8 | 2023 | 52 | 3.870 |
Why?
| | Wounds and Injuries | 18 | 2025 | 755 | 2.940 |
Why?
| | Cholecystitis, Acute | 7 | 2024 | 23 | 2.900 |
Why?
| | Cholecystitis | 5 | 2023 | 24 | 2.150 |
Why?
| | Trauma Centers | 18 | 2025 | 419 | 1.880 |
Why?
| | Venous Thromboembolism | 6 | 2025 | 313 | 1.810 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2822 | 1.380 |
Why?
| | Anticoagulants | 7 | 2025 | 664 | 1.310 |
Why?
| | Appendicitis | 4 | 2020 | 130 | 1.270 |
Why?
| | Hemorrhage | 9 | 2024 | 721 | 1.170 |
Why?
| | Emergency Treatment | 2 | 2020 | 118 | 1.160 |
Why?
| | Postoperative Complications | 7 | 2021 | 2639 | 1.010 |
Why?
| | Retrospective Studies | 42 | 2025 | 15510 | 1.010 |
Why?
| | Cholecystectomy | 4 | 2024 | 60 | 0.980 |
Why?
| | Resuscitation | 9 | 2024 | 250 | 0.960 |
Why?
| | Appendectomy | 3 | 2020 | 79 | 0.850 |
Why?
| | Thrombelastography | 4 | 2021 | 153 | 0.800 |
Why?
| | Injury Severity Score | 13 | 2025 | 521 | 0.790 |
Why?
| | Enoxaparin | 4 | 2023 | 63 | 0.790 |
Why?
| | Blood Coagulation | 3 | 2021 | 255 | 0.790 |
Why?
| | Adult | 49 | 2025 | 37643 | 0.770 |
Why?
| | Simulation Training | 2 | 2022 | 99 | 0.740 |
Why?
| | Burns | 4 | 2023 | 325 | 0.740 |
Why?
| | Middle Aged | 44 | 2025 | 33239 | 0.730 |
Why?
| | Operative Time | 7 | 2023 | 143 | 0.710 |
Why?
| | Time-to-Treatment | 2 | 2020 | 204 | 0.710 |
Why?
| | Abdomen | 2 | 2018 | 125 | 0.700 |
Why?
| | Rib Fractures | 1 | 2021 | 32 | 0.690 |
Why?
| | Prospective Studies | 19 | 2025 | 7573 | 0.680 |
Why?
| | Laparoscopy | 3 | 2022 | 464 | 0.680 |
Why?
| | Machine Learning | 2 | 2023 | 488 | 0.670 |
Why?
| | Shock, Hemorrhagic | 5 | 2024 | 167 | 0.670 |
Why?
| | Length of Stay | 8 | 2021 | 1205 | 0.660 |
Why?
| | Artificial Intelligence | 1 | 2023 | 275 | 0.660 |
Why?
| | Nerve Block | 1 | 2021 | 73 | 0.660 |
Why?
| | Pain Management | 2 | 2021 | 348 | 0.660 |
Why?
| | Emergency Medical Services | 2 | 2023 | 547 | 0.650 |
Why?
| | Critical Pathways | 1 | 2021 | 88 | 0.650 |
Why?
| | Humans | 85 | 2025 | 136803 | 0.650 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 363 | 0.630 |
Why?
| | Specialties, Surgical | 1 | 2020 | 74 | 0.610 |
Why?
| | Male | 55 | 2025 | 67330 | 0.610 |
Why?
| | Balloon Occlusion | 3 | 2024 | 34 | 0.610 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 180 | 0.600 |
Why?
| | Kaolin | 1 | 2018 | 4 | 0.600 |
Why?
| | Factor Xa | 1 | 2018 | 32 | 0.600 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 44 | 0.600 |
Why?
| | Female | 57 | 2025 | 72816 | 0.590 |
Why?
| | Vitamin K | 1 | 2018 | 45 | 0.590 |
Why?
| | Hemostatics | 1 | 2018 | 52 | 0.570 |
Why?
| | Airway Extubation | 1 | 2018 | 57 | 0.570 |
Why?
| | End Stage Liver Disease | 1 | 2019 | 82 | 0.560 |
Why?
| | Embolization, Therapeutic | 3 | 2024 | 229 | 0.560 |
Why?
| | Atrial Flutter | 1 | 2017 | 35 | 0.540 |
Why?
| | Tachycardia, Supraventricular | 1 | 2017 | 43 | 0.540 |
Why?
| | Internship and Residency | 4 | 2022 | 1133 | 0.530 |
Why?
| | Appendix | 1 | 2017 | 30 | 0.530 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1044 | 0.510 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 225 | 0.510 |
Why?
| | Orthopedic Procedures | 1 | 2019 | 216 | 0.500 |
Why?
| | Blood Transfusion | 3 | 2021 | 324 | 0.500 |
Why?
| | Algorithms | 1 | 2023 | 1690 | 0.490 |
Why?
| | Texas | 5 | 2019 | 241 | 0.480 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2022 | 0.470 |
Why?
| | Patient Safety | 1 | 2018 | 308 | 0.470 |
Why?
| | Treatment Outcome | 17 | 2024 | 10748 | 0.460 |
Why?
| | Endovascular Procedures | 3 | 2024 | 315 | 0.460 |
Why?
| | Critical Illness | 2 | 2019 | 804 | 0.460 |
Why?
| | Biomedical Research | 1 | 2021 | 688 | 0.460 |
Why?
| | Aged | 22 | 2025 | 23808 | 0.440 |
Why?
| | Surgeons | 3 | 2025 | 296 | 0.420 |
Why?
| | Hospitalization | 3 | 2022 | 2184 | 0.410 |
Why?
| | Practice Guidelines as Topic | 4 | 2025 | 1572 | 0.400 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 389 | 0.400 |
Why?
| | Clinical Competence | 2 | 2022 | 1094 | 0.380 |
Why?
| | Mass Screening | 4 | 2023 | 1267 | 0.380 |
Why?
| | Liver | 3 | 2024 | 1940 | 0.360 |
Why?
| | Hand-Assisted Laparoscopy | 1 | 2010 | 3 | 0.340 |
Why?
| | Wandering Spleen | 1 | 2010 | 2 | 0.340 |
Why?
| | Operating Rooms | 3 | 2022 | 123 | 0.320 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3265 | 0.310 |
Why?
| | Head Injuries, Penetrating | 1 | 2009 | 5 | 0.310 |
Why?
| | Risk Assessment | 10 | 2021 | 3434 | 0.310 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2020 | 82 | 0.310 |
Why?
| | Abdominal Injuries | 2 | 2020 | 123 | 0.300 |
Why?
| | Safety-net Providers | 3 | 2019 | 119 | 0.300 |
Why?
| | Abdominal Abscess | 2 | 2020 | 27 | 0.300 |
Why?
| | Logistic Models | 4 | 2024 | 2067 | 0.290 |
Why?
| | Geriatric Assessment | 2 | 2020 | 224 | 0.290 |
Why?
| | Time Factors | 9 | 2020 | 6809 | 0.290 |
Why?
| | Emergency Service, Hospital | 5 | 2024 | 2048 | 0.290 |
Why?
| | Multiple Trauma | 1 | 2009 | 100 | 0.290 |
Why?
| | Blood Coagulation Tests | 2 | 2018 | 67 | 0.280 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2024 | 20 | 0.270 |
Why?
| | Hospitals | 2 | 2022 | 684 | 0.270 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2018 | 53 | 0.270 |
Why?
| | Blood Coagulation Disorders | 2 | 2021 | 172 | 0.270 |
Why?
| | Wounds, Gunshot | 2 | 2017 | 220 | 0.270 |
Why?
| | Aorta | 3 | 2024 | 417 | 0.260 |
Why?
| | Triage | 1 | 2009 | 221 | 0.260 |
Why?
| | Quality Improvement | 4 | 2024 | 1163 | 0.250 |
Why?
| | Young Adult | 11 | 2023 | 13129 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 6 | 2025 | 2668 | 0.250 |
Why?
| | Choledocholithiasis | 2 | 2015 | 16 | 0.240 |
Why?
| | Brain Injuries | 2 | 2025 | 494 | 0.240 |
Why?
| | Facial Bones | 1 | 2025 | 30 | 0.230 |
Why?
| | Cause of Death | 3 | 2017 | 430 | 0.230 |
Why?
| | Facial Injuries | 1 | 2025 | 21 | 0.230 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 2024 | 3 | 0.230 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2025 | 94 | 0.230 |
Why?
| | Skull Fractures | 1 | 2025 | 36 | 0.230 |
Why?
| | Wound Infection | 1 | 2025 | 32 | 0.230 |
Why?
| | Hepatic Artery | 1 | 2024 | 61 | 0.230 |
Why?
| | Hematoma | 1 | 2024 | 53 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 115 | 0.210 |
Why?
| | Workload | 1 | 2025 | 160 | 0.210 |
Why?
| | Glasgow Coma Scale | 3 | 2025 | 184 | 0.210 |
Why?
| | Registries | 4 | 2024 | 2015 | 0.210 |
Why?
| | Venous Thrombosis | 1 | 2025 | 190 | 0.200 |
Why?
| | Adolescent | 7 | 2023 | 21385 | 0.200 |
Why?
| | Aged, 80 and over | 6 | 2020 | 7593 | 0.200 |
Why?
| | Pelvic Bones | 1 | 2024 | 128 | 0.190 |
Why?
| | ROC Curve | 2 | 2022 | 545 | 0.190 |
Why?
| | Health Plan Implementation | 2 | 2020 | 139 | 0.190 |
Why?
| | Time Perception | 1 | 2022 | 28 | 0.190 |
Why?
| | Surveys and Questionnaires | 5 | 2023 | 5744 | 0.180 |
Why?
| | Patient Handoff | 1 | 2021 | 32 | 0.180 |
Why?
| | Paraspinal Muscles | 1 | 2021 | 14 | 0.180 |
Why?
| | General Surgery | 2 | 2020 | 169 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2024 | 276 | 0.180 |
Why?
| | Intubation, Intratracheal | 1 | 2023 | 257 | 0.170 |
Why?
| | Liver Failure, Acute | 1 | 2021 | 65 | 0.170 |
Why?
| | Hospital Mortality | 6 | 2021 | 901 | 0.170 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 116 | 0.170 |
Why?
| | Trauma Severity Indices | 1 | 2021 | 106 | 0.170 |
Why?
| | Altitude | 1 | 2025 | 485 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1462 | 0.170 |
Why?
| | Anesthetics, Local | 1 | 2021 | 80 | 0.170 |
Why?
| | Risk Factors | 7 | 2024 | 10332 | 0.160 |
Why?
| | Bias | 1 | 2021 | 218 | 0.160 |
Why?
| | Soft Tissue Infections | 1 | 2020 | 37 | 0.160 |
Why?
| | Laparotomy | 1 | 2020 | 109 | 0.160 |
Why?
| | United States Social Security Administration | 1 | 2019 | 2 | 0.160 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 136 | 0.160 |
Why?
| | Diphenoxylate | 1 | 2019 | 5 | 0.160 |
Why?
| | Ileus | 1 | 2019 | 12 | 0.160 |
Why?
| | Loperamide | 1 | 2019 | 11 | 0.160 |
Why?
| | Clinical Protocols | 2 | 2019 | 267 | 0.160 |
Why?
| | Metoclopramide | 1 | 2019 | 19 | 0.160 |
Why?
| | Erythromycin | 1 | 2019 | 25 | 0.160 |
Why?
| | Mycoses | 1 | 2020 | 79 | 0.160 |
Why?
| | Antifungal Agents | 1 | 2020 | 136 | 0.160 |
Why?
| | Fasciitis, Necrotizing | 1 | 2019 | 15 | 0.160 |
Why?
| | Fractures, Bone | 1 | 2024 | 376 | 0.160 |
Why?
| | Diet Therapy | 1 | 2019 | 37 | 0.160 |
Why?
| | Surgicenters | 1 | 2019 | 6 | 0.160 |
Why?
| | Violence | 2 | 2023 | 257 | 0.160 |
Why?
| | United States | 12 | 2025 | 14691 | 0.160 |
Why?
| | Abdominal Wound Closure Techniques | 1 | 2018 | 7 | 0.150 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 127 | 0.150 |
Why?
| | Viscoelastic Substances | 1 | 2018 | 10 | 0.150 |
Why?
| | Hospitals, University | 1 | 2019 | 182 | 0.150 |
Why?
| | Dabigatran | 1 | 2018 | 22 | 0.150 |
Why?
| | Conversion to Open Surgery | 1 | 2018 | 16 | 0.150 |
Why?
| | Program Evaluation | 2 | 2020 | 889 | 0.150 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2020 | 179 | 0.150 |
Why?
| | Pipecolic Acids | 1 | 2018 | 26 | 0.150 |
Why?
| | Publishing | 1 | 2020 | 145 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 65 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 159 | 0.150 |
Why?
| | Diarrhea | 1 | 2019 | 183 | 0.150 |
Why?
| | Photoperiod | 1 | 2018 | 52 | 0.150 |
Why?
| | Bandages | 1 | 2018 | 37 | 0.150 |
Why?
| | Antithrombins | 1 | 2018 | 60 | 0.140 |
Why?
| | Brain Injuries, Traumatic | 1 | 2023 | 355 | 0.140 |
Why?
| | Efficiency, Organizational | 1 | 2019 | 139 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2021 | 305 | 0.140 |
Why?
| | Myocardial Contusions | 1 | 2017 | 1 | 0.140 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 117 | 0.140 |
Why?
| | Emergencies | 1 | 2018 | 164 | 0.140 |
Why?
| | Thorax | 1 | 2017 | 49 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2020 | 228 | 0.140 |
Why?
| | Sex Factors | 2 | 2021 | 2064 | 0.140 |
Why?
| | Multidetector Computed Tomography | 1 | 2017 | 39 | 0.140 |
Why?
| | Surgical Procedures, Operative | 1 | 2020 | 258 | 0.140 |
Why?
| | Enteral Nutrition | 1 | 2019 | 201 | 0.140 |
Why?
| | Thoracic Vertebrae | 1 | 2017 | 77 | 0.140 |
Why?
| | Electronic Health Records | 1 | 2025 | 1046 | 0.140 |
Why?
| | Tachycardia | 1 | 2017 | 57 | 0.140 |
Why?
| | Incidence | 3 | 2019 | 2797 | 0.140 |
Why?
| | Spinal Injuries | 1 | 2017 | 51 | 0.140 |
Why?
| | Accidental Falls | 1 | 2020 | 193 | 0.130 |
Why?
| | Patient Transfer | 1 | 2019 | 168 | 0.130 |
Why?
| | Police | 1 | 2017 | 39 | 0.130 |
Why?
| | Smartphone | 1 | 2018 | 92 | 0.130 |
Why?
| | Blood Viscosity | 1 | 2016 | 17 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 172 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 102 | 0.130 |
Why?
| | Occupational Injuries | 1 | 2017 | 44 | 0.130 |
Why?
| | Arginine | 1 | 2018 | 271 | 0.130 |
Why?
| | Photography | 1 | 2017 | 95 | 0.130 |
Why?
| | Heparin | 1 | 2018 | 259 | 0.130 |
Why?
| | Cohort Studies | 3 | 2020 | 5704 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2025 | 1798 | 0.130 |
Why?
| | Physical Therapy Modalities | 1 | 2020 | 308 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1127 | 0.130 |
Why?
| | Rivaroxaban | 1 | 2018 | 255 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 587 | 0.130 |
Why?
| | Blood Loss, Surgical | 1 | 2016 | 100 | 0.120 |
Why?
| | Radiography, Interventional | 1 | 2016 | 113 | 0.120 |
Why?
| | Substance Abuse Detection | 1 | 2017 | 87 | 0.120 |
Why?
| | Critical Care | 1 | 2021 | 583 | 0.120 |
Why?
| | Blood Safety | 1 | 2015 | 11 | 0.120 |
Why?
| | Lumbar Vertebrae | 1 | 2017 | 245 | 0.120 |
Why?
| | Platelet Transfusion | 1 | 2016 | 67 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2017 | 117 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 223 | 0.110 |
Why?
| | Cryopreservation | 1 | 2015 | 98 | 0.110 |
Why?
| | Sulfonamides | 1 | 2018 | 513 | 0.110 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2018 | 462 | 0.110 |
Why?
| | Benchmarking | 1 | 2015 | 183 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 481 | 0.110 |
Why?
| | Watchful Waiting | 2 | 2024 | 80 | 0.110 |
Why?
| | Exsanguination | 1 | 2013 | 19 | 0.110 |
Why?
| | Angiography | 2 | 2024 | 207 | 0.100 |
Why?
| | Erythrocyte Transfusion | 1 | 2015 | 193 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1507 | 0.100 |
Why?
| | Burn Units | 3 | 2019 | 48 | 0.100 |
Why?
| | International Cooperation | 1 | 2014 | 198 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 328 | 0.100 |
Why?
| | Chronic Pain | 1 | 2017 | 260 | 0.100 |
Why?
| | Patient Discharge | 1 | 2019 | 894 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2016 | 418 | 0.090 |
Why?
| | Antifibrinolytic Agents | 1 | 2012 | 51 | 0.090 |
Why?
| | Blood Preservation | 1 | 2015 | 283 | 0.090 |
Why?
| | Age Factors | 5 | 2020 | 3286 | 0.090 |
Why?
| | Suicide | 1 | 2018 | 645 | 0.090 |
Why?
| | Child Abuse | 1 | 2016 | 528 | 0.080 |
Why?
| | Surgical Mesh | 1 | 2010 | 47 | 0.080 |
Why?
| | Propensity Score | 2 | 2025 | 289 | 0.080 |
Why?
| | Gastrointestinal Motility | 2 | 2019 | 27 | 0.080 |
Why?
| | Malaria | 1 | 2010 | 63 | 0.080 |
Why?
| | Splanchnic Circulation | 1 | 2009 | 10 | 0.080 |
Why?
| | Tungsten | 1 | 2009 | 30 | 0.080 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 81 | 0.080 |
Why?
| | Survival Rate | 3 | 2020 | 1964 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2009 | 145 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5106 | 0.070 |
Why?
| | Acute Disease | 2 | 2023 | 1007 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2025 | 546 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2017 | 1069 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1351 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 935 | 0.060 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2021 | 211 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2021 | 1316 | 0.060 |
Why?
| | Ultrasonography | 2 | 2023 | 752 | 0.060 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2025 | 33 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1231 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2828 | 0.060 |
Why?
| | Radiology, Interventional | 1 | 2024 | 33 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2025 | 197 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2024 | 125 | 0.050 |
Why?
| | Common Bile Duct | 1 | 2023 | 17 | 0.050 |
Why?
| | Comorbidity | 2 | 2019 | 1614 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 47 | 0.050 |
Why?
| | Sex Chromosome Aberrations | 2 | 1982 | 64 | 0.050 |
Why?
| | Hypoxia | 1 | 2009 | 1112 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 273 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5424 | 0.040 |
Why?
| | Contrast Media | 1 | 2024 | 462 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1936 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2020 | 92 | 0.040 |
Why?
| | Antidiarrheals | 1 | 2019 | 15 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 678 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 668 | 0.040 |
Why?
| | Necrosis | 1 | 2020 | 245 | 0.040 |
Why?
| | Debridement | 1 | 2019 | 81 | 0.040 |
Why?
| | Gastrointestinal Agents | 1 | 2019 | 65 | 0.040 |
Why?
| | Educational Measurement | 1 | 2022 | 280 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2019 | 57 | 0.040 |
Why?
| | Europe | 1 | 2020 | 413 | 0.040 |
Why?
| | Fungi | 1 | 2020 | 144 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 323 | 0.040 |
Why?
| | Population Dynamics | 1 | 2019 | 149 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 105 | 0.040 |
Why?
| | Acetaminophen | 1 | 2021 | 266 | 0.040 |
Why?
| | Growth Disorders | 1 | 1979 | 86 | 0.040 |
Why?
| | Hospital Costs | 1 | 2019 | 116 | 0.040 |
Why?
| | Infant | 4 | 2023 | 9395 | 0.040 |
Why?
| | Organizational Innovation | 1 | 2019 | 138 | 0.040 |
Why?
| | Prognosis | 2 | 2018 | 4013 | 0.040 |
Why?
| | Safety | 1 | 2020 | 338 | 0.040 |
Why?
| | California | 1 | 2019 | 429 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 382 | 0.030 |
Why?
| | Child, Preschool | 4 | 2023 | 10997 | 0.030 |
Why?
| | Military Personnel | 1 | 2024 | 544 | 0.030 |
Why?
| | Postural Balance | 1 | 2020 | 216 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2017 | 143 | 0.030 |
Why?
| | Homicide | 1 | 2017 | 66 | 0.030 |
Why?
| | Probability | 1 | 2017 | 304 | 0.030 |
Why?
| | Counseling | 1 | 2019 | 388 | 0.030 |
Why?
| | Burns, Chemical | 1 | 2016 | 32 | 0.030 |
Why?
| | Accidents, Traffic | 1 | 2017 | 189 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 951 | 0.030 |
Why?
| | Elasticity | 1 | 2016 | 197 | 0.030 |
Why?
| | Learning | 1 | 2020 | 407 | 0.030 |
Why?
| | Biliary Tract | 1 | 2015 | 17 | 0.030 |
Why?
| | Self-Injurious Behavior | 1 | 2017 | 129 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 642 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 61 | 0.030 |
Why?
| | Communication | 1 | 2021 | 875 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 817 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2020 | 539 | 0.030 |
Why?
| | Blood Banks | 1 | 2015 | 41 | 0.030 |
Why?
| | Liver Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 390 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2017 | 216 | 0.030 |
Why?
| | Reference Values | 1 | 2017 | 816 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2015 | 133 | 0.030 |
Why?
| | Risk | 1 | 2017 | 908 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 431 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 521 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1693 | 0.030 |
Why?
| | Liver Diseases | 1 | 2017 | 311 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1262 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1321 | 0.030 |
Why?
| | India | 1 | 2014 | 193 | 0.030 |
Why?
| | Guatemala | 1 | 2014 | 326 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2012 | 47 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2710 | 0.020 |
Why?
| | Partial Thromboplastin Time | 1 | 2012 | 57 | 0.020 |
Why?
| | Platelet Count | 1 | 2012 | 86 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 82 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 271 | 0.020 |
Why?
| | Child | 3 | 2023 | 21819 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3556 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1982 | 0.020 |
Why?
| | Alcoholism | 1 | 2017 | 804 | 0.020 |
Why?
| | Venules | 1 | 2009 | 14 | 0.020 |
Why?
| | Mesocricetus | 1 | 2009 | 39 | 0.020 |
Why?
| | Reperfusion | 1 | 2009 | 40 | 0.020 |
Why?
| | Cricetinae | 1 | 2009 | 289 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2751 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 6729 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2486 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1982 | 185 | 0.010 |
Why?
| | Growth | 1 | 1982 | 60 | 0.010 |
Why?
| | Aneuploidy | 1 | 1982 | 89 | 0.010 |
Why?
| | Follicle Stimulating Hormone | 2 | 1982 | 244 | 0.010 |
Why?
| | Diet | 1 | 2009 | 1274 | 0.010 |
Why?
| | Rats | 1 | 2009 | 5639 | 0.010 |
Why?
| | Y Chromosome | 1 | 1979 | 11 | 0.010 |
Why?
| | X Chromosome | 1 | 1979 | 53 | 0.010 |
Why?
| | Bone Development | 1 | 1979 | 54 | 0.010 |
Why?
| | Child Development | 1 | 1982 | 464 | 0.010 |
Why?
| | Intellectual Disability | 1 | 1979 | 164 | 0.010 |
Why?
| | Infant, Newborn | 2 | 1982 | 6032 | 0.010 |
Why?
| | Animals | 1 | 2009 | 36850 | 0.000 |
Why?
| | Psychology, Child | 1 | 1982 | 38 | 0.000 |
Why?
| | Sexual Maturation | 1 | 1982 | 55 | 0.000 |
Why?
| | Body Height | 1 | 1982 | 199 | 0.000 |
Why?
| | Gonadal Steroid Hormones | 1 | 1982 | 140 | 0.000 |
Why?
| | Body Weight | 1 | 1982 | 985 | 0.000 |
Why?
| | Longitudinal Studies | 1 | 1982 | 2829 | 0.000 |
Why?
|
|
Cripps's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|